March 14 (Reuters) - Merck & Co Inc
* Merck provides update on supplemental biologics license application (sbla) for keytruda® (pembrolizumab) in previously treated advanced microsatellite instability-high cancer
* Merck & co inc - new fda target action date is june 9, 2017
* Merck & co-submission of additional data is considered major amendment to sbla under pdufa, thus extending target action date by three months Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.